{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:33:04Z","timestamp":1788827584496,"version":"build-2803163510"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01720-z","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:37:34Z","timestamp":1761817054000},"page":"1358-1373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)"],"prefix":"10.1007","volume":"27","author":[{"given":"Sarafina Urenna","family":"Otis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"3","key":"1720_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1720_CR2","doi-asserted-by":"crossref","unstructured":"Wistuba I, Brambilla E, Noguchi M. Chapter 17: Classic anatomic pathology and lung cancer. In: Pass HI, Ball D, Scagliotti GV, editors. IASLC Thoracic Oncology, 2nd ed.. Philadelphia: Elsevier; 2018. p. 143\u20136.","DOI":"10.1016\/B978-0-323-52357-8.00017-2"},{"issue":"1","key":"1720_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"F Detterbeck","year":"2017","unstructured":"Detterbeck F, Boffa D, Kim A, Tanoue L. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193\u2013203.","journal-title":"Chest"},{"issue":"12","key":"1720_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"key":"1720_CR5","unstructured":"Amin MB (ed). AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer, 2017. pp. 431\u2013455."},{"issue":"1","key":"1720_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"key":"1720_CR7","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","volume":"30","author":"J Vansteenkiste","year":"2019","unstructured":"Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019;30:1244\u201353.","journal-title":"Ann Oncol"},{"issue":"1","key":"1720_CR8","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1038\/bjc.2015.48","volume":"112","author":"RD Neal","year":"2015","unstructured":"Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. Br J Cancer. 2015;112(1):S92\u2013107.","journal-title":"Br J Cancer"},{"key":"1720_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398:535\u201354.","journal-title":"Lancet"},{"key":"1720_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1378\/chest.06-3096","volume":"132","author":"DJ Raz","year":"2007","unstructured":"Raz DJ, Zell JA, Ou S-HI, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193\u20139.","journal-title":"Chest"},{"key":"1720_CR11","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ejcts\/ezx127","volume":"52","author":"K Sekihara","year":"2017","unstructured":"Sekihara K, Hishida T, Yoshida J, et al. Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is cured from postoperative recurrence? Eur J Cardiothorac Surg. 2017;52:522\u20138.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1720_CR12","first-page":"242","volume":"3","author":"H Uramoto","year":"2014","unstructured":"Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 2014;3:242\u20139.","journal-title":"Transl Lung Cancer Res"},{"key":"1720_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","volume":"383","author":"NSCLC Meta-analysis Collaborative Group","year":"2014","unstructured":"NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561\u201371.","journal-title":"Lancet"},{"key":"1720_CR14","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552\u20139.","journal-title":"J Clin Oncol"},{"key":"1720_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2021.09.003","volume":"162","author":"C Aggarwal","year":"2021","unstructured":"Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, et al. Molecular testing in stage I-III non-small cell lung cancer: approaches and challenges. Lung Cancer. 2021;162:42\u201353.","journal-title":"Lung Cancer"},{"key":"1720_CR16","doi-asserted-by":"crossref","unstructured":"Shields MD, Marin-Acevedo JA, Pellini B. Immunotherapy for advanced non-small cell lung cancer: A decade of progress. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting; 2021. pp. 41:1\u201323.","DOI":"10.1200\/EDBK_321483"},{"issue":"2","key":"1720_CR17","first-page":"117","volume":"21","author":"J Wang","year":"2023","unstructured":"Wang J, Wu L. First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects. Cancer Biol Med. 2023;21(2):117\u201324.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"1720_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","volume":"27","author":"K Ganesh","year":"2021","unstructured":"Ganesh K, Massagu\u00e9 J. Targeting metastatic cancer. Nat Med. 2021;27(1):34\u201344.","journal-title":"Nat Med"},{"key":"1720_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.010","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, et al. Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer. J Thorac Oncol. 2024;19(10):1373\u20131414. https:\/\/doi.org\/10.1016\/j.jtho.2024.06.010","journal-title":"J Thorac Oncol"},{"key":"1720_CR20","unstructured":"United States Food and Drug Administration. FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer. October 15. 2021. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer. Accessed 1 Aug 2024"},{"key":"1720_CR21","unstructured":"United States Food and Drug Administration. FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer. March 2. 2022. Available at:\u00a0https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-nivolumab-and-platinum-doublet-chemotherapy-early-stage-non-small-cell-lung. Accessed 1 Aug 2024"},{"key":"1720_CR22","unstructured":"European Commission approves Roche\u2019s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer. News release. Roche. June 9. 2022. Available at:\u00a0https:\/\/bit.ly\/3xOWv6S.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR23","unstructured":"United States Food and Drug Administration. FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer. News release. FDA. January 26. 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR24","unstructured":"National Institute for Health and Care Excellence. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer: Technology appraisal guidance [TA876]. March 22. 2023. Available at: https:\/\/www.nice.org.uk\/guidance\/ta876.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR25","unstructured":"Bristol Myers Squibb receives European Commission approval for Opdivo (nivolumab) with chemotherapy as neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in patients with tumor cell PD-L1 expression\u2009\u2265\u20091%. News release. Bristol Myers Squibb. June 29. 2023. Available at:\u00a0https:\/\/news.bms.com\/news\/corporate-financial\/2023\/.\u00a0Accessed\u00a01 August 2024"},{"key":"1720_CR26","unstructured":"European Commission approves Keytruda (pembrolizumab) as adjuvant treatment for adults with non-small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy. News release. Merck. October 16. 2023. Available at: https:\/\/www.merck.com\/news\/european-commission-approves-keytruda-pembrolizumab-as-adjuvant-treatment-for-adults-with-non-small-cell-lung-cancer-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based\/.\u00a0Accessed 1 Aug 2024."},{"key":"1720_CR27","unstructured":"United States Food and Drug Administration. FDA approves neoadjuvant\/ adjuvant pembrolizumab for resectable non-small lung cancer. October 16. 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvant-adjuvant-pembrolizumab-resectable-non-small-cell-lung-cancer. Accessed 1 Aug 2024"},{"key":"1720_CR28","unstructured":"European Commission approves Merck\u2019s Keytruda (pembrolizumab) plus chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults. News release. Merck. March 28. 2024. Available at: https:\/\/www.merck.com\/news\/european-commission-approves-mercks-keytruda-pembrolizumab-plus-chemotherapy-as-neoadjuvant-treatment-then-continued-as-monotherapy-as-adjuvant-treatment-for-resectable-non-small-ce\/.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR29","unstructured":"United States Food and Drug Administration. FDA approves n eoadjuvant\/adjuvant durvalumab for resectable non-small cell lung cancer. August 15. 2024. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer.\u00a0Accessed 20 Aug 2024."},{"key":"1720_CR30","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]; In development [GID-A11174]. Expected publication date:16 October 2024. Available at: https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11174.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR31","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer: Technology appraisal guidance [TA1037]. February 5. 2025. Available at: https:\/\/www.nice.org.uk\/guidance\/ta1037\/chapter\/1-Recommendation.\u00a0Accessed 27 Aug 2025"},{"key":"1720_CR32","unstructured":"National Institute for Health and Care Excellence. Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer: Technology appraisal guidance [TA1071]. June 19, 2025. Available at: https:\/\/www.nice.org.uk\/guidance\/ta1071\/chapter\/1-Recommendations.\u00a0Accessed 27 Aug 2025"},{"issue":"21","key":"1720_CR33","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"key":"1720_CR34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","volume":"15","author":"WD Travis","year":"2020","unstructured":"Travis WD, Dacic S, Wistuba I, et al. IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 2020;15:709\u201340.","journal-title":"J Thorac Oncol"},{"key":"1720_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010","volume":"42","author":"J Spicer","year":"2024","unstructured":"Spicer J, et al. Neoadjuvant nivolumab (NIVO)\u2009+\u2009chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from checkmate 816. JCO. 2024;42:LBA8010\u20138010.","journal-title":"JCO"},{"issue":"8","key":"1720_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa2502931","volume":"393","author":"PM Forde","year":"2025","unstructured":"Forde PM, Spicer JD, Provencio M, et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med. 2025;393(8):741\u201352. https:\/\/doi.org\/10.1056\/NEJMoa2502931.","journal-title":"N Engl J Med"},{"issue":"10312","key":"1720_CR37","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(21)02135-8","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C, et al. Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10312):1686.","journal-title":"Lancet"},{"issue":"10","key":"1720_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant Atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907\u201319.","journal-title":"Ann Oncol"},{"issue":"21","key":"1720_CR39","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1200\/JCO-24-01681","volume":"43","author":"E Felip","year":"2025","unstructured":"Felip E, Altorki N, Zhou C, et al. Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non-small cell lung cancer (IMpower010): an open-label, randomized, phase III trial. J Clin Oncol. 2025;43(21):2343\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1720_CR40","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","volume":"23","author":"M O\u2019Brien","year":"2022","unstructured":"O\u2019Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274\u201386.","journal-title":"Lancet Oncol"},{"key":"1720_CR41","unstructured":"National Cancer Institute. The ALCHEMIST Lung Cancer Trials. January 24. 2024. Available at:\u00a0https:\/\/www.cancer.gov\/types\/lung\/research\/alchemist.\u00a0Accessed 1 Aug 2024"},{"issue":"6","key":"1720_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491\u2013503.","journal-title":"N Engl J Med"},{"issue":"10459","key":"1720_CR43","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","volume":"404","author":"JD Spicer","year":"2024","unstructured":"Spicer JD, Garassino MC, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;404(10459):1240\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(24)01756-2.","journal-title":"Lancet"},{"issue":"19","key":"1720_CR44","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, He J, Lu S, Sepesi B, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390(19):1756\u201369.","journal-title":"N Engl J Med"},{"issue":"18","key":"1720_CR45","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"2","key":"1720_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, et al. Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13(2):119\u201329.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1720_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, et al. Perioperative Toripalimab plus chemotherapy for patients with resectable Non-Small cell lung cancer: the Neotorch randomized clinical trial. JAMA. 2024;331(3):201\u201311.","journal-title":"JAMA"},{"issue":"4","key":"1720_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.6837","volume":"7","author":"GL Banna","year":"2024","unstructured":"Banna GL, Hassan MA, Signori A, Giunta EF, Maniam A, Anpalakhan S, et al. Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4):e246837.","journal-title":"JAMA Netw Open"},{"key":"1720_CR49","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1200\/JCO.23.00258","volume":"41","author":"M Christine","year":"2023","unstructured":"Christine M, Bestvina, et al. Early-Stage lung cancer: using Circulating tumor DNA to get personal. JCO. 2023;41:4093\u20136.","journal-title":"JCO"},{"key":"1720_CR50","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/tlcr-22-106","volume":"11","author":"D Yue","year":"2022","unstructured":"Yue D, Liu W, Chen C, et al. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients. Transl Lung Cancer Res. 2022;11:263\u201376.","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"1720_CR51","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.21037\/tlcr-23-570","volume":"12","author":"N Deboever","year":"2023","unstructured":"Deboever N, Zhang J. The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer-thoughts from the KEYNOTE-671 trial. Transl Lung Cancer Res. 2023;12(11):2347\u201352.","journal-title":"Transl Lung Cancer Res"},{"key":"1720_CR52","unstructured":"Clinicaltrials.gov. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030). 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03456063.\u00a0Accessed 1 Aug 2024."},{"issue":"9","key":"1720_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2217\/imt-2021-0019","volume":"13","author":"JM Sands","year":"2021","unstructured":"Sands JM, Mandrekar SJ, Kozono D, et al. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. 2021;13(9):727\u201334.","journal-title":"Immunotherapy"},{"key":"1720_CR54","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer"},{"key":"1720_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino M, Hatabu H, Hodi FS. Imaging of cancer immunotherapy: current approaches and future directions. Radiology. 2019;290:9\u201322.","journal-title":"Radiology"},{"key":"1720_CR56","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-020-04711-3","volume":"47","author":"X Tao","year":"2020","unstructured":"Tao X, Li N, Wu N, et al. The efficiency of 18F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable nonsmall cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1720_CR57","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(13)70158-X","volume":"14","author":"A Mauguen","year":"2013","unstructured":"Mauguen A, Pignon JP, Burdett S, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients\u2019 data. Lancet Oncol. 2013;14(7):619\u201326.","journal-title":"Lancet Oncol"},{"issue":"7","key":"1720_CR58","first-page":"749","volume":"29","author":"H West","year":"2023","unstructured":"West H, Hu X, Zhang S, et al. Evaluation of disease-free survival as a predictor of overall survival and assessment of real-world burden of disease recurrence in resected early-stage non-small cell lung cancer. J Manag Care Spec Pharm. 2023;29(7):749\u201357.","journal-title":"J Manag Care Spec Pharm"},{"key":"1720_CR59","doi-asserted-by":"publisher","first-page":"175883592311984","DOI":"10.1177\/17588359231198446","volume":"15","author":"RB Cameron","year":"2023","unstructured":"Cameron RB, Hines JB, Torri V, et al. What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?>. Ther Adv Med Oncol. 2023;15:17588359231198446. https:\/\/doi.org\/10.1177\/17588359231198446.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"1720_CR60","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","volume":"19","author":"JB Hines","year":"2024","unstructured":"Hines JB, Cameron RB, Esposito A, Kim L, Porcu L, Nuccio A, et al. Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint Blockade in resectable in NSCLC. J Thorac Oncol. 2024;19(7):1108\u201316.","journal-title":"J Thorac Oncol"},{"key":"1720_CR61","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40:2924\u201333.","journal-title":"J Clin Oncol"},{"key":"1720_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01701-2","author":"M Maffezzoli","year":"2025","unstructured":"Maffezzoli M, Nagpal R, Elewaily M, et al. The role of circulating tumor DNA in patients treated with adjuvant immune checkpoint inhibitors: clinical reality or distant horizon? Curr Oncol Rep. 2025. https:\/\/doi.org\/10.1007\/s11912-025-01701-2.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"1720_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1200\/OP.23.00014","volume":"19","author":"D Uprety","year":"2023","unstructured":"Uprety D, West HJ. Perioperative therapy for resectable non-small-cell lung cancer: weighing options for the present and future. JCO Oncol Pract. 2023;19(7):403\u20139.","journal-title":"JCO Oncol Pract"},{"key":"1720_CR64","doi-asserted-by":"publisher","first-page":"1129465","DOI":"10.3389\/fimmu.2023.1129465","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou S, Yang H. Immunotherapy resistance in non-small-cell lung cancer: from mechanism to clinical strategies. Front Immunol. 2023;14:1129465.","journal-title":"Front Immunol"},{"issue":"34","key":"1720_CR65","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1111\/1759-7714.15157","volume":"14","author":"D Huang","year":"2023","unstructured":"Huang D, Lin G, Chu Q, Hu Y, Wang J, Wang Z, et al. Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer. Thorac Cancer. 2023;14(34):3421\u20139.","journal-title":"Thorac Cancer"},{"issue":"18","key":"1720_CR66","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711\u201323.","journal-title":"N Engl J Med"},{"key":"1720_CR67","unstructured":"United States Food and Drug Administration. (2020) FDA approves osimertinib as adjuvant therapy for non-small cell lung. December 18, 2020. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR68","unstructured":"Tagrisso approved in the EU for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer. News release. AstraZeneca. May 28. 2021. Available at: https:\/\/bit.ly\/2RKhYM5.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR69","unstructured":"OncLive. (2021) Adjuvant osimertinib approved in Europe for early-stage EGFR\u2009+\u2009NSCLC, OncLive. Available at: https:\/\/www.onclive.com\/view\/adjuvant-osimertinib-approved-in-europe-for-early-stage-egfr-nsclc.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR70","unstructured":"National Institute for Health and Care Excellence. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection. January 19. 2022. Available at: https:\/\/www.nice.org.uk\/guidance\/TA761.\u00a0Accessed 1 Aug 2024"},{"issue":"9","key":"1720_CR71","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725\u201337.","journal-title":"Br J Cancer"},{"issue":"2","key":"1720_CR72","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR- mutated non\u2013small cell lung cancer\u2013a meta-analysis. J Thorac Oncol. 2017;12(2):403\u20137.","journal-title":"J Thorac Oncol"},{"issue":"18","key":"1720_CR73","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585\u201393.","journal-title":"Clin Cancer Res"},{"key":"1720_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.922899","volume":"12","author":"T Ma","year":"2022","unstructured":"Ma T, Jiao J, Huo R, Li X, Fang G, Zhao Q, et al. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. Front Oncol. 2022;12:922899.","journal-title":"Front Oncol"},{"issue":"2","key":"1720_CR75","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41416-020-01099-7","volume":"124","author":"BC Creelan","year":"2021","unstructured":"Creelan BC, Yeh TC, Kim S-W, Nogami N, Kim D-W, Chow LQM, et al. A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced\/metastatic non-small-cell lung cancer. Br J Cancer. 2021;124(2):383\u201390.","journal-title":"Br J Cancer"},{"issue":"11","key":"1720_CR76","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","volume":"16","author":"MA Socinski","year":"2021","unstructured":"Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16(11):1909\u201324.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1720_CR77","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1759-7714.13039","volume":"10","author":"T Uchida","year":"2019","unstructured":"Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, et al. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and\/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer. 2019;10(4):975\u20139.","journal-title":"Thorac Cancer"},{"issue":"5","key":"1720_CR78","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/annonc\/mdz077","volume":"30","author":"AJ Schoenfeld","year":"2019","unstructured":"Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, et al. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Ann Oncol. 2019;30(5):839\u201344.","journal-title":"Ann Oncol"},{"key":"1720_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1349502","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Yu G, Jin K, Qian J. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies. Front Immunol. 2024;15:1349502. https:\/\/doi.org\/10.3389\/fimmu.2024.1349502.","journal-title":"Front Immunol"},{"issue":"34","key":"1720_CR80","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1111\/1759-7714.15126","volume":"14","author":"S Su","year":"2023","unstructured":"Su S, Chen F, Xu M, Liu B, Wang L. Recent advances in neoantigen vaccines for treating non-small cell lung cancer. Thorac Cancer. 2023;14(34):3361\u20138.","journal-title":"Thorac Cancer"},{"issue":"12","key":"1720_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121953","volume":"17","author":"X Li","year":"2025","unstructured":"Li X, Zhu YJ, Xue Y, Chen TT, Sun XK, Shi HY. Neoantigen-based immunotherapy in lung cancer: advances, challenges and prospects. Cancers (Basel). 2025;17(12):1953.","journal-title":"Cancers (Basel)"},{"key":"1720_CR82","unstructured":"ClinicalTrials.gov. A Study of Pembrolizumab With or Without V940 in Participants With Non\u2013small Cell Lung Cancer. ClinicalTrials.gov identifier: NCT06623422. Updated July 28, 2025. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06623422.\u00a0Accessed 25 Aug 2025"},{"key":"1720_CR83","unstructured":"ClinicalTrials.gov. A study of pembrolizumab (MK\u20133475) with or without intismeran autogene (V940) in participants with non\u2013small cell lung cancer. ClinicalTrials.gov identifier: NCT06077760. Updated August 28, 2025. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06623422.\u00a0Accessed 28 Aug 2025."},{"issue":"5","key":"1720_CR84","first-page":"217","volume":"22","author":"JE Reuss","year":"2024","unstructured":"Reuss JE, Rosner S, Levy BP. Antibody-drug conjugates in advanced lung cancer: is this a new frontier? Clin Adv Hematol Oncol. 2024;22(5):217\u201326.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"1720_CR85","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.annonc.2024.04.002","volume":"35","author":"S Peters","year":"2024","unstructured":"Peters S, Loi S, Andr\u00e9 F, Chandarlapaty S, Felip E, Finn SP, et al. Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG partners foundation. Ann Oncol. 2024;35(7):607\u201329.","journal-title":"Ann Oncol"},{"issue":"6","key":"1720_CR86","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s11912-024-01524-7","volume":"26","author":"A Ghose","year":"2024","unstructured":"Ghose A, Lapitan P, Apte V, Ghosh A, Kandala A, Basu S, et al. Antibody drug conjugates in urological cancers: a review of the current landscape. Curr Oncol Rep. 2024;26(6):633\u201346.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1720_CR87","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1093\/oncolo\/oyad233","volume":"28","author":"PV Bhardwaj","year":"2023","unstructured":"Bhardwaj PV, Abdou YG. The evolving landscape of immune checkpoint inhibitors and antibody drug conjugates in the treatment of early-stage breast cancer. Oncologist. 2023;28(10):832\u201344.","journal-title":"Oncologist"},{"issue":"6","key":"1720_CR88","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.21037\/apm-22-1350","volume":"12","author":"M Uccello","year":"2023","unstructured":"Uccello M, Adeleke S, Moschetta M, Ghose A, Boussios S. Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence. Ann Palliat Med. 2023;12(6):1345\u201354.","journal-title":"Ann Palliat Med"},{"key":"1720_CR89","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer. April 13th, 2021. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-enfortumab-vedotin-ejfv-locally-advanced-or-metastatic-urothelial-cancer.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR90","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer. April 13, 2021. Available at: https:\/\/bit.ly\/3tgxmgy.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR91","unstructured":"United States Food and Drug Administratin. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer. FDA. December 15. 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR92","unstructured":"Enhertu approved in the EU as the first HER2 directed therapy for patients with HER2 mutant advanced non-small cell lung cancer. News release. Daiichi Sankyo. October 23. 2023. Available at: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202310\/20231023_E.pdf.\u00a0Accessed 1 Aug 2024"},{"key":"1720_CR93","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. August 11. 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung.\u00a0Accessed 1 Aug 2024."},{"key":"1720_CR94","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression. May 14. 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression.\u00a0Accessed 25 Aug 2025"},{"key":"1720_CR95","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to Datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. June 25, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer.\u00a0Accessed 25 Aug 2025"},{"issue":"31","key":"1720_CR96","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II destiny-lung02 trial. J Clin Oncol. 2023;41(31):4852\u201363.","journal-title":"J Clin Oncol"},{"key":"1720_CR97","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, Bar J, Horinouchi H, Goldman J, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II luminosity trial. J Clin Oncol. 2024;42:3000\u201311.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1720_CR98","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO.24.01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn M-J, Lisberg A, et al. Datopotamab Deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025;43(10):1254\u201365. https:\/\/doi.org\/10.1200\/JCO.24.01349.","journal-title":"J Clin Oncol"},{"issue":"26suppl","key":"1720_CR99","first-page":"LBA12","volume":"42","author":"MJ Ahn","year":"2024","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab Deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. J Clin Oncol. 2024;42(26suppl):LBA12.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1720_CR100","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III tropion-lung01 study. J Clin Oncol. 2025;43(3):260\u201372.","journal-title":"J Clin Oncol"},{"key":"1720_CR101","doi-asserted-by":"publisher","first-page":"9004","DOI":"10.1200\/JCO.2023.41.16_suppl.9004","volume":"41","author":"Y Goto","year":"2023","unstructured":"Goto Y, et al. TROPION-Lung02: Datopotamab Deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC). JCO. 2023;41:9004\u20139004.","journal-title":"JCO"},{"key":"1720_CR102","doi-asserted-by":"publisher","unstructured":"Levy B, Paz\u2013Ares L, Lin CC et al. TROPION\u2013Lung02: Datopotamab deruxtecan (Dato\u2013DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt\u2013CT) as first\u2013line (1L) therapy for advanced non\u2013small cell lung cancer (aNSCLC). Presented at: 2025 ASCO Annual Meeting; May 30\u2013June 3, 2025; Chicago, IL. Abstract 8501. Available from: https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8501.\u00a0Accessed 25 Aug 2025","DOI":"10.1200\/JCO.2025.43.16_suppl.8501"},{"issue":"16suppl","key":"1720_CR103","doi-asserted-by":"publisher","first-page":"TPS3158","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3158","volume":"41","author":"H Borghaei","year":"2023","unstructured":"Borghaei H, Waqar SN, Bruno DS, et al. TROPION-Lung04: phase 1b, multicenter study of Datopotamab Deruxtecan (Dato-DXd) in combination with immunotherapy\u2009\u00b1\u2009carboplatin in advanced\/metastatic non-small cell lung cancer (mNSCLC). J Clin Oncol. 2023;41(16suppl):TPS3158.","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"1720_CR104","doi-asserted-by":"publisher","first-page":"104164","DOI":"10.1016\/j.esmoop.2025.104164","volume":"10","author":"K Cuppens","year":"2025","unstructured":"Cuppens K, Papadopoulos KP, Nishio M, et al. First-line (1L) Datopotamab Deruxtecan (Dato-DXd)\u2009+\u2009durvalumab\u2009\u00b1\u2009carboplatin in advanced or metastatic non-small cell lung cancer (a\/mNSCLC): results from TROPION-Lung04 (cohorts 2 and 4). ESMO Open. 2025;10(suppl 2):104164. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104164.","journal-title":"ESMO Open"},{"key":"1720_CR105","unstructured":"ClinicalTrials.gov. Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07). August 30, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05555732.\u00a0Accessed 30 Aug 2024"},{"issue":"21","key":"1720_CR106","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon-2023-0230","volume":"19","author":"BP Levy","year":"2023","unstructured":"Levy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, et al. TROPION-Lung08: phase III study of Datopotamab Deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023;19(21):1461\u201372.","journal-title":"Future Oncol"},{"key":"1720_CR107","unstructured":"ClinicalTrials.gov, Phase III. Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR). August 12, 2024. Available at:\u00a0https:\/\/www.clinicaltrials.gov\/study\/NCT05687266.\u00a0Accessed 30 Aug 2024"},{"key":"1720_CR108","unstructured":"ClinicalTrials.gov. Phase Ib study of the safety of T-DXd and immunotherapy agents with and without chemotherapy in advanced or metastatic HER2+, Non-squamous NSCLC (DL03). August 27, 2024. Available at:\u00a0https:\/\/www.clinicaltrials.gov\/study\/NCT04686305.\u00a0Accessed 30 August 2024"},{"key":"1720_CR109","unstructured":"ClinicalTrials.gov. DS8201a and pembrolizumab in participants with locally advanced\/\u200bmetastatic breast or Non-Small Cell Lung Cancer. August 7. 2024. Available at:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT04042701.\u00a0Accessed 30 Aug 2024"},{"key":"1720_CR110","doi-asserted-by":"publisher","unstructured":"Hong S, Wang Q, Cheng Y, et al. First-line sacituzumab Tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med Published Online August; 2025. p. 19. https:\/\/doi.org\/10.1038\/s41591-025-03883-5.","DOI":"10.1038\/s41591-025-03883-5"},{"key":"1720_CR111","unstructured":"ClinicalTrials.gov. Sacituzumab Tirumotecan (MK-2870) in combination with pembrolizumab versus pembrolizumab alone in metastatic Non-small Cell Lung Cancer (NSCLC) with Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS)\u2009\u2265\u200950% (MK-2870-007). August 30, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06170788.\u00a0Accessed 30 Aug 2024"},{"key":"1720_CR112","unstructured":"ClinicalTrials.gov. Study of Pembrolizumab (MK-3475) Monotherapy versus sacituzumab govitecan in combination with pembrolizumab for participants with metastatic Non-small Cell Lung Cancer (NSCLC) with Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS)\u2009\u2265\u200950% (MK-3475-D46). June 27, 2024. Available at:https:\/\/clinicaltrials.gov\/study\/NCT05609968.\u00a0Accessed 1 Aug 2024"},{"issue":"11","key":"1720_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","volume":"24","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023;24(11):9674.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1720_CR114","doi-asserted-by":"publisher","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","volume":"7","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554.","journal-title":"ESMO Open"},{"key":"1720_CR115","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F, Spira AI, Lisberg AE et al. TROPION-PanTumor01: dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 9058]. J Clin Oncol. 2021;39(15).","DOI":"10.1200\/JCO.2021.39.15_suppl.9058"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01720-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01720-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:02:49Z","timestamp":1765432969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01720-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":115,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1720"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01720-z","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}